The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon's multiple streams framework.
Hepatitis C
Iran
Kingdon’s multiple streams framework
agenda-setting
health policy
Journal
Health research policy and systems
ISSN: 1478-4505
Titre abrégé: Health Res Policy Syst
Pays: England
ID NLM: 101170481
Informations de publication
Date de publication:
27 Mar 2019
27 Mar 2019
Historique:
received:
12
09
2018
accepted:
10
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Hepatitis C virus (HCV) infection causes a large number of deaths annually worldwide. Policies play an important role in regulating healthcare agendas and prioritising of health-related issues. Understanding these priorities is very important in health. The objective of this study was to investigate HCV-related issues and their influence on agenda-setting in Iran. A qualitative design was used. Data were collected by carrying out a review of documents and interviews. A comprehensive search was conducted to identify documents related to HCV-related policies in Iran. Semi-structured interviews were conducted with both purposive and snowball sampling of 14 interviewees related to the HCV programme in Iran, including government officials, civil society, development partnership members and academicians. Documents and interview data were analysed manually and using MAXQDA Version 10 software. Kingdon's multiple streams framework was used to guide data analysis. The factors which influenced HCV-related agenda-setting were lack of proper information of the HCV epidemiology before the 1990s, lack of diagnostic facilities, neighbouring countries with high HCV prevalence, the stigma of HCV, high prevalence in prisoners, international evidence and high costs generated by HCV. The factors related to policy were effective treatment methods, drug production inside Iran, Iran Hepatitis Network, support outside government group elites and academicians. The factors related to political will were international influence, changes in the government and parliament support. The findings of this study showed that there are various national and international factors that play a role in shaping HCV-related policies. It seems that, if HCV is put into the agenda, it can be eliminated in Iran by 2030 by supporting and implementing appropriate programmes from decision- and policy-makers.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) infection causes a large number of deaths annually worldwide. Policies play an important role in regulating healthcare agendas and prioritising of health-related issues. Understanding these priorities is very important in health. The objective of this study was to investigate HCV-related issues and their influence on agenda-setting in Iran.
METHODS
METHODS
A qualitative design was used. Data were collected by carrying out a review of documents and interviews. A comprehensive search was conducted to identify documents related to HCV-related policies in Iran. Semi-structured interviews were conducted with both purposive and snowball sampling of 14 interviewees related to the HCV programme in Iran, including government officials, civil society, development partnership members and academicians. Documents and interview data were analysed manually and using MAXQDA Version 10 software. Kingdon's multiple streams framework was used to guide data analysis.
RESULTS
RESULTS
The factors which influenced HCV-related agenda-setting were lack of proper information of the HCV epidemiology before the 1990s, lack of diagnostic facilities, neighbouring countries with high HCV prevalence, the stigma of HCV, high prevalence in prisoners, international evidence and high costs generated by HCV. The factors related to policy were effective treatment methods, drug production inside Iran, Iran Hepatitis Network, support outside government group elites and academicians. The factors related to political will were international influence, changes in the government and parliament support.
CONCLUSION
CONCLUSIONS
The findings of this study showed that there are various national and international factors that play a role in shaping HCV-related policies. It seems that, if HCV is put into the agenda, it can be eliminated in Iran by 2030 by supporting and implementing appropriate programmes from decision- and policy-makers.
Identifiants
pubmed: 30917837
doi: 10.1186/s12961-019-0436-z
pii: 10.1186/s12961-019-0436-z
pmc: PMC6438031
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30Références
Health Res Policy Syst. 2003 Jan 13;1(1):2
pubmed: 12646071
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
Health Promot Int. 2006 Mar;21(1):1-4
pubmed: 16452127
Afr J Reprod Health. 2004 Dec;8(3):6-10
pubmed: 17348321
Lancet. 2007 Oct 13;370(9595):1370-9
pubmed: 17933652
Health Policy Plan. 2008 Sep;23(5):294-307
pubmed: 18650209
Prev Chronic Dis. 2010 Jul;7(4):A77
pubmed: 20550835
Infect Dis Clin North Am. 2011 Sep;25(3):593-9, viii
pubmed: 21896360
PLoS Med. 2012;9(3):e1001187
pubmed: 22448147
J Adv Nurs. 2013 Nov;69(11):2413-22
pubmed: 23448572
N Engl J Med. 2013 May 16;368(20):1878-87
pubmed: 23607594
BMC Health Serv Res. 2013 Aug 19;13:324
pubmed: 23958173
BMC Pregnancy Childbirth. 2013 Sep 30;13:181
pubmed: 24079699
Clin Infect Dis. 2014 Apr;58(8):1055-61
pubmed: 24523214
Hosp Pharm. 2014 Apr;49(4):405-6
pubmed: 24958948
Health Res Policy Syst. 2014 Sep 18;12:53
pubmed: 25231603
J Health Polit Policy Law. 2015 Feb;40(1):195-219
pubmed: 25480850
Am J Public Health. 2015 Apr;105(4):e58-61
pubmed: 25713966
PLoS Med. 2015 Mar 10;12(3):e1001795
pubmed: 25757228
Ann Intern Med. 2015 Mar 17;162(6):397-406
pubmed: 25775312
Public Health. 2015 Jun;129(6):698-704
pubmed: 25795018
Health Promot Int. 2016 Dec;31(4):769-781
pubmed: 26092852
Int J Infect Dis. 2015 Nov;40:116-30
pubmed: 26460088
Int J Health Policy Manag. 2015 Aug 31;4(10):637-40
pubmed: 26673172
Int J Health Policy Manag. 2015 Sep 24;5(1):23-31
pubmed: 26673646
Health Policy Plan. 2016 Jul;31(6):683-90
pubmed: 26758539
Policy Polit Nurs Pract. 2016 Feb;17(1):5-14
pubmed: 26880726
Indian J Community Med. 2016 Jan-Mar;41(1):1-4
pubmed: 26917865
J Hepatol. 2016 Jun;64(6):1240-6
pubmed: 26921686
J Viral Hepat. 2016 Jul;23(7):522-34
pubmed: 26924428
Gastroenterol Hepatol (N Y). 2015 Nov;11(11):778-80
pubmed: 27134594
Am J Public Health. 2016 Jun;106(6):975-6
pubmed: 27153012
Policy Polit Nurs Pract. 2016 May;17(2):66-75
pubmed: 27257080
Int J Health Policy Manag. 2016 Feb 09;5(6):355-63
pubmed: 27285513
Clinicoecon Outcomes Res. 2016 Aug 08;8:377-85
pubmed: 27540306
Med J Islam Repub Iran. 2016 Jul 03;30:392
pubmed: 27579283
BMC Health Serv Res. 2016 Sep 29;16(1):522
pubmed: 27682853
Middle East J Dig Dis. 2016 Jul;8(3):189-200
pubmed: 27698968
World J Virol. 2016 Nov 12;5(4):170-182
pubmed: 27878104
J Infect Dev Ctries. 2016 Nov 24;10(11):1162-1167
pubmed: 27886027
BMJ Open. 2017 Jan 13;7(1):e013340
pubmed: 28087549
AIDS Behav. 2017 Mar;21(3):611-614
pubmed: 28144791
J Viral Hepat. 2017 Apr;24(4):262-267
pubmed: 28145032
CMAJ Open. 2017 Feb 03;5(1):E97-E108
pubmed: 28401125
Prev Med. 2017 Jul;100:123-131
pubmed: 28435081
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):447-448
pubmed: 28743936
Global Health. 2017 Aug 1;13(1):52
pubmed: 28764720
World J Hepatol. 2017 Aug 28;9(24):1040-1042
pubmed: 28932350
BMJ Glob Health. 2017 Jul 28;2(2):e000318
pubmed: 29081999
JMIR Public Health Surveill. 2017 Dec 15;3(4):e91
pubmed: 29246882
Bull World Health Organ. 2018 Jan 1;96(1):51-58
pubmed: 29403100
World J Hepatol. 2018 Feb 27;10(2):186-212
pubmed: 29527256
Rand Health Q. 2018 Apr 1;7(3):1
pubmed: 29607245
Health Econ Policy Law. 2019 Jan;14(1):29-39
pubmed: 29655400
Harm Reduct J. 2018 May 9;15(1):24
pubmed: 29739400
Health Commun. 2018 Jun 11;:1-10
pubmed: 29889549
Health Res Policy Syst. 2019 Feb 6;17(1):15
pubmed: 30728042